Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AXSM NYSE:BHVN NASDAQ:NUVL NASDAQ:RYTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXSMAxsome Therapeutics$109.25+3.8%$105.69$75.56▼$139.13$5.45B0.51779,820 shs326,397 shsBHVNBiohaven$14.16+5.2%$14.60$12.79▼$55.70$1.45B0.981.68 million shs891,758 shsNUVLNuvalent$78.23+2.1%$78.91$55.53▼$113.51$5.62B1.3545,393 shs107,771 shsRYTMRhythm Pharmaceuticals$98.87+2.5%$76.60$43.57▼$99.02$6.57B2.38668,819 shs260,701 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXSMAxsome Therapeutics+1.22%+1.58%-3.44%+1.50%+23.92%BHVNBiohaven+0.27%-11.53%-3.10%-31.01%-63.59%NUVLNuvalent+2.21%-2.56%-5.34%+7.87%+6.18%RYTMRhythm Pharmaceuticals+2.28%+8.91%+11.26%+68.40%+116.86%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAXSMAxsome Therapeutics4.8221 of 5 stars4.53.00.04.52.54.20.6BHVNBiohaven3.1868 of 5 stars4.51.00.00.02.22.50.6NUVLNuvalent3.1031 of 5 stars4.51.00.00.02.33.30.0RYTMRhythm Pharmaceuticals3.4015 of 5 stars2.52.00.04.32.60.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXSMAxsome Therapeutics 3.07Buy$178.0062.93% UpsideBHVNBiohaven 3.07Buy$53.75279.48% UpsideNUVLNuvalent 3.09Buy$119.6052.89% UpsideRYTMRhythm Pharmaceuticals 3.07Buy$101.572.73% UpsideCurrent Analyst Ratings BreakdownLatest BHVN, RYTM, NUVL, and AXSM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/12/2025BHVNBiohavenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$54.00 ➝ $30.008/12/2025BHVNBiohavenLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$60.00 ➝ $50.008/12/2025BHVNBiohavenMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$63.00 ➝ $54.008/12/2025BHVNBiohavenRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$57.00 ➝ $52.008/12/2025BHVNBiohavenBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$50.00 ➝ $49.008/7/2025RYTMRhythm PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$80.00 ➝ $100.008/6/2025RYTMRhythm PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$119.00 ➝ $120.008/6/2025RYTMRhythm PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$130.00 ➝ $135.008/5/2025RYTMRhythm PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$100.00 ➝ $109.008/5/2025AXSMAxsome TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$173.00 ➝ $176.008/5/2025AXSMAxsome TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$184.00 ➝ $189.00(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXSMAxsome Therapeutics$495.03M11.01N/AN/A$1.46 per share74.83BHVNBiohavenN/AN/AN/AN/A$4.19 per shareN/ANUVLNuvalentN/AN/AN/AN/A$13.09 per shareN/ARYTMRhythm Pharmaceuticals$156.29M42.02N/AN/A($0.18) per share-549.28Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXSMAxsome Therapeutics-$287.22M-$5.07N/A38.74N/A-49.88%-283.22%-33.06%N/ABHVNBiohaven-$846.42M-$7.66N/AN/AN/AN/A-230.34%-145.21%8/14/2025 (Estimated)NUVLNuvalent-$260.76M-$4.90N/AN/AN/AN/A-32.58%-30.14%8/14/2025 (Estimated)RYTMRhythm Pharmaceuticals-$260.60M-$3.01N/AN/AN/A-117.13%-1,831.43%-48.33%N/ALatest BHVN, RYTM, NUVL, and AXSM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q1 2025BHVNBiohaven-$1.94-$1.94N/A-$1.94$0.41 millionN/A8/7/2025Q2 2025NUVLNuvalent-$1.27-$1.31-$0.04-$1.39N/AN/A8/5/2025Q2 2025RYTMRhythm Pharmaceuticals-$0.66-$0.75-$0.09-$0.75$43.72 million$48.50 million8/4/2025Q2 2025AXSMAxsome Therapeutics-$1.00-$0.92+$0.08-$0.97$140.02 million$150.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAXSMAxsome TherapeuticsN/AN/AN/AN/AN/ABHVNBiohavenN/AN/AN/AN/AN/ANUVLNuvalentN/AN/AN/AN/AN/ARYTMRhythm PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXSMAxsome Therapeutics1.661.571.51BHVNBiohavenN/A2.332.33NUVLNuvalentN/A13.5713.57RYTMRhythm PharmaceuticalsN/A2.792.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXSMAxsome Therapeutics81.49%BHVNBiohaven88.78%NUVLNuvalent97.26%RYTMRhythm PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipAXSMAxsome Therapeutics22.40%BHVNBiohaven14.60%NUVLNuvalent10.20%RYTMRhythm Pharmaceuticals6.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAXSMAxsome Therapeutics38049.90 million38.72 millionOptionableBHVNBiohaven239102.11 million87.21 millionOptionableNUVLNuvalent4071.81 million64.48 millionOptionableRYTMRhythm Pharmaceuticals14066.42 million62.37 millionOptionableBHVN, RYTM, NUVL, and AXSM HeadlinesRecent News About These CompaniesRhythm Pharmaceuticals (NASDAQ:RYTM) Sets New 1-Year High - What's Next?2 hours ago | marketbeat.comPersistent Asset Partners Ltd Sells 6,811 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)August 13 at 7:05 AM | marketbeat.comAnalysts Are Bullish on Top Healthcare Stocks: Rhythm Pharmaceuticals (RYTM), Krystal Biotech (KRYS)August 13 at 2:13 AM | theglobeandmail.comGuggenheim Keeps Their Buy Rating on Rhythm Pharmaceuticals (RYTM)August 13 at 2:13 AM | theglobeandmail.comHC Wainwright Brokers Increase Earnings Estimates for RYTMAugust 11 at 2:43 AM | marketbeat.comLeerink Partnrs Has Positive Outlook of RYTM Q3 EarningsAugust 10 at 2:31 AM | americanbankingnews.comLeerink Partners Keeps Their Buy Rating on Rhythm Pharmaceuticals (RYTM)August 9, 2025 | theglobeandmail.comLeerink Partnrs Issues Positive Outlook for RYTM EarningsAugust 9, 2025 | marketbeat.comHC Wainwright Forecasts Strong Price Appreciation for Rhythm Pharmaceuticals (NASDAQ:RYTM) StockAugust 8, 2025 | marketbeat.comLoss-Making Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Expected To Breakeven In The Medium-TermAugust 7, 2025 | finance.yahoo.comGuggenheim Issues Positive Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock PriceAugust 7, 2025 | marketbeat.comJMP Securities Issues Positive Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock PriceAugust 7, 2025 | marketbeat.comRhythm Pharmaceuticals (NASDAQ:RYTM) Posts Earnings Results, Misses Estimates By $0.09 EPSAugust 6, 2025 | marketbeat.comPrimecap Management Co. CA Sells 783,868 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)August 6, 2025 | marketbeat.com17,100 Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Purchased by Jefferies Financial Group Inc.August 6, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. (RYTM) Q2 2025 Earnings Call TranscriptAugust 5, 2025 | seekingalpha.comRhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue EstimatesAugust 5, 2025 | zacks.comRhythm Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business UpdateAugust 5, 2025 | globenewswire.comBIT Capital GmbH Takes $319,000 Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)August 4, 2025 | marketbeat.comWestfield Capital Management Co. LP Takes $71.04 Million Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)August 4, 2025 | marketbeat.comBayforest Capital Ltd Acquires New Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)August 2, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBHVN, RYTM, NUVL, and AXSM Company DescriptionsAxsome Therapeutics NASDAQ:AXSM$109.25 +4.02 (+3.82%) As of 02:08 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.Biohaven NYSE:BHVN$14.16 +0.69 (+5.15%) As of 02:08 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.Nuvalent NASDAQ:NUVL$78.22 +1.62 (+2.11%) As of 02:08 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.Rhythm Pharmaceuticals NASDAQ:RYTM$98.87 +2.41 (+2.50%) As of 02:08 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave Pulls Back Into a Screaming Buy Intel's White House Reset: From Political Storm to a Clearer Sky AST SpaceMobile on Track for Explosive Upside Oklo’s Stock Is Set up for a Correction—Buy It When It Bounces If Qualcomm Holds $145, Its Next Move Could Be Massive Alphabet Reclaims $200 Threshold—Bull Run Reignited? NFL and WWE Land on ESPN—The Impact on Disney and TKO Stocks Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access